A 10-Week Memantine Treatment in Bipolar Depression: A Case Report. Focus on Depressive Symptomatology, Cognitive Parameters and Quality of Life
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Memantine and other glutamatergic agents have been currently investigated in some off-label indications due to glutamatergic involvement in several psychoneurological disorders. We assumed that memantine similarly to ketamine may positively influence mood, moreover having a potential to improve cognition and general quality of life. We report a case of a 49-year-old male hospitalized during a manic and a subsequent moderate depressive episode. After an ineffective use of lithium, olanzapine and antidepressive treatment with mianserin, memantine was added up to 20 mg per day for 10 weeks. The mental state was assessed using the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Hamilton Anxiety Scale, the Clinical Global Inventory, the World Health Organization Quality of Life Scale and psychological tests. After 10 weeks the patient achieved a partial symptomatic improvement in mood, anxiety and quality of sleep, but his activity remained insufficient. We also observed an improvement in the parameters of cognitive functioning and quality of life. There was neither significant mood variations during the memantine use nor mood changes after its termination. No significant side effects were noted during the memantine treatment. We conclude that using memantine in bipolar depression may improve mood, cognitive functioning and quality of life.
Abstract
Memantine and other glutamatergic agents have been currently investigated in some off-label indications due to glutamatergic involvement in several psychoneurological disorders. We assumed that memantine similarly to ketamine may positively influence mood, moreover having a potential to improve cognition and general quality of life. We report a case of a 49-year-old male hospitalized during a manic and a subsequent moderate depressive episode. After an ineffective use of lithium, olanzapine and antidepressive treatment with mianserin, memantine was added up to 20 mg per day for 10 weeks. The mental state was assessed using the Hamilton Depression Rating Scale, the Young Mania Rating Scale, the Hamilton Anxiety Scale, the Clinical Global Inventory, the World Health Organization Quality of Life Scale and psychological tests. After 10 weeks the patient achieved a partial symptomatic improvement in mood, anxiety and quality of sleep, but his activity remained insufficient. We also observed an improvement in the parameters of cognitive functioning and quality of life. There was neither significant mood variations during the memantine use nor mood changes after its termination. No significant side effects were noted during the memantine treatment. We conclude that using memantine in bipolar depression may improve mood, cognitive functioning and quality of life.
참고문헌 (27)
- Tuominen HJ, "Glutamatergic drugs for schizophrenia", Cochrane Database Syst Rev, 19, pp.CD003730~ (2006)
- Nagy J, "Alcohol related changes in regulation of NMDA receptor functions", Curr Neuropharmacol, 6, pp.39~54 (2008)
- Pittenger C, "Riluzole in the treatment of mood and anxiety disorders", CNS Drugs, 22, pp.761~786 (2008)
- Larkin GL, "A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department", Int J Neuropsychopharmacol, 14, pp.1127~1131 (2011)
- Zajączkowski W, "Uncompetitive NMDA receptor antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP", Neuropharmacology, 36, pp.961~971 (1997)
- Parsons CG, "Memantine is a clinically well tolerated N-methyl-D-apartate (NMDA) receptor antagonist - a review of preclinical data", Neuropharmacology, 38, pp.735~767 (1999)
- Standridge JB, "Pharmacotherapeutic approaches to the treatment of Alzheimer’s disease", Clin Ther, 26, pp.615~630 (2004)
- "Ebixa (Memantine) Monograph" (2012)[URL]
- Permoda-Osip A, "Glutamatergic conception of mood disorders", Psychiatr Pol, 45, pp.875~888 (2011)
- Zarate CA Jr, "An open-label trial of riluzole in patients with treatment-resistant major depression", Am J Psychiatry, 161, pp.171~174 (2004)
- Ferguson JM, "An open-label, flexible-dose study of memantine in major depressive disorder", Clin Neuropharmacol, 30, pp.136~144 (2007)
- Koukopoulos A, "The sustained mood-stabilizing effect of memantine in the management of treatment resistant bipolar disorders: findings from a 12-month naturalistic trial", J Affect Disord, 136, pp.163~166 (2012)
- Anand A, "Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial", Bipolar Disord, 14, pp.64~70 (2012)
- Keck PE Jr, "Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: a pilot evaluation", Clin Neuropharmacol, 32, pp.199~204 (2009)
- Muhonen LH, "Double-blind, randomized comparison of memantine and escitalopram for the treatment of major depressive disorder comorbid with alcohol dependence", J Clin Psychiatry, 69, pp.392~399 (2008)
- Muhonen LH, "Treatment of alcohol dependence in patients with co-morbid major depressive disorder -- predictors for the outcomes with memantine and escitalopram medication", Subst Abuse Treat Prev Policy, 3, pp.20~ (2008)
- Teng CT, "Memantine may acutely improve cognition and have a mood stabilizing effect in treatment-resistant bipolar disorder", Rev Bras Psiquiatr, 28, pp.252~254 (2006)
- Munoz C, "Memantine in major depression with catatonic features", J Neuropsychiatry Clin Neurosci, 20, pp.119~120 (2008)
- Obregon DF, "Memantine and catatonia: a case report and literature review", J Psychiatr Pract, 17, pp.292~299 (2011)
- Northoff G, "What catatonia can tell us about “top-down modulation”: a neuropsychiatric hypothesis", Behav Brain Sci, 25, pp.555~577 (2002)
- Agarwal V, "Memantine in the management of a clinically challenging case of bipolar disorder", Indian J Psychiatry, 51, pp.137~138 (2009)
- Martínez-Arán A, "Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder", Am J Psychiatry, 161, pp.262~270 (2004)
- Osher Y, "Computerized testing of neurocognitive function in euthymic bipolar patients compared to those with mild cognitive impairment and cognitively healthy controls", Psychother Psychosom, 80, pp.298~303 (2011)
- Sani G, "The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence", CNS Drugs, 26, pp.663~690 (2012)
- Koukopoulos A, "Antimanic and mood-stabilizing effect of memantine as an augmenting agent in treatment-resistant bipolar disorder", Bipolar Disord, 12, pp.348~349 (2010)
- Witkin JM, "New approaches to the pharmacological management of major depressive disorder", Adv Pharmacol, 57, pp.347~379 (2009)
- Enz R., "Metabotropic glutamate receptors and interacting proteins: evolving drug targets", Curr Drug Targets, 13, pp.145~156 (2012)